Toward achieving optimal response: Understanding and managing antidepressant side effects

Dialogues in Clinical Neuroscience

Volumn 10, Issue 4, 2008, Pages 409-418

  Kelly, Karen ^a,b   Posternak, Michael ^b,c   Alpert, Jonathan E ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antidepressant; Depression; Remission; Selective serotonin reuptake inhibitor; Side effect

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DEXAMPHETAMINE; DIPHENOXYLATE; DULOXETINE; FLUOXETINE; GINKGO BILOBA EXTRACT; LAXATIVE; LEPIDIUM MEYENII EXTRACT; LOPERAMIDE; MIRTAZAPINE; MOCLOBEMIDE; MODAFINIL; NEFAZODONE; OMEPRAZOLE; PAROXETINE; PLACEBO; PRAMIPEXOLE; PROTRIPTYLINE; RANITIDINE; REBOXETINE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; YOHIMBINE; ZOLPIDEM;

APATHY; COGNITIVE THERAPY; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE DURATION; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; LIBIDO DISORDER; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; METHODOLOGY; NAUSEA; NAUSEA AND VOMITING; ORGASM DISORDER; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PREDICTION; PREVALENCE; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; SLEEP DISORDER; SLEEP TIME; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FORECASTING; HUMANS; PATIENT COMPLIANCE; RECURRENCE;

EID: 59149101471     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65:959-965.
2. Bull SA, Hu XU, Hunkeler EM. et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288:1403-1409.
3. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting I: beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(suppl 22):30-33.
4. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity and burden of side effects. J Psychiatr Pract. 2006; 12:71-79.
5. Clyde DJ. SAFTEE: data system for side effect assessment scale. Psychopharmacol Bull. 1986;22:287.
6. Nelson JC, Jatlow P, Quinlan DM. Subjective side effects during desipramine treatment. Arch Gen Psychiatry. 1984;41:55-59.
7. Rush AJ. Giles DE. Schlesser MA. Fulton CL. Weissenburger J. Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 1986;18:65-87.
8. Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67-74.
9. Papakostas, GI. Limitations of contemporary antidepressants:tolerability. J Clin Psychiatry. 2007;68(suppl 10):11-17.
10. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuation or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578-584.
11. Hunter AM. Cook IA. Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. [122 refs] Psych Clin N Am. 2007;30:105-124. Review.
12. Iosifescu DV, Renshaw PF, Lyoo IK, et al. Brain white-matter hyperintensites and treatment outcome in major depressive disorder. Br J Psychiatry. 2006;188:180-185.
13. Trindade D, Menon D, Topfer L, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ-JAMC. 1998;159:1245-1252.
14. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60:1350-1355.
15. Papakostas GI, Nelson JC, Kasper S, Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2008;18:122-127.
16. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry. 1996;58(suppl 2):46-52.
17. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry. 1996;57(suppl 2):53-62.
18. Berlanga C, Arechavaleta B, Heinze G, et al. A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients. Salud Mental. 1997;20:1-8.
19. Montgomery SA, Huusom AK, Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50:57-64.
20. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65:1190-1196.
21. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006;14:361-370.
22. Nelson JC, Prtichett YL, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry. 2006;8:212-219.
23. Goldstien DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2002;63:225-231.
24. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry. 2006;51:783-790.
25. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. J Psychopharmacol. In press.
26. Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52:294-299.
27. Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry. 2001;62(suppl 3):35-43.
28. Montejo-Gonzalez AL, Llorca G, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23:176-94.
29. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;3:357-366.
30. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61:656-663.
31. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol. 2003;10:305-314.
32. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol. 2003;18:133-141.
33. Phillip M, Tiller JW, Baier D, et al. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults: the Australian and German Study Groups. Eur Neuropsychopharmacol. 2000;10:305-314.
34. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al. Comparison on the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;18:133-141.
35. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62(suppl 3):10-21.
36. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry. 2000;61(suppl 11):28-36.
37. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152:1514-1516.
38. Bartlik BD, Kaplan P, Kaplan HS. Psychostimulans apparently reverse sexual dysfunction secondary to selective serotonin reuptake inhibitors. J Sex Marital Ther. 1995;21:264-271.
39. Herman JB, Brotman AW, Pollack MH, et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1990;51:25-27.
40. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med. 1995;25:191-201.
41. Nurnberg HG, Henslely PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil. JAMA. 2003;289:56-64.
42. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008; 300:395-404.
43. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66:974-981.
44. Falk WE, Roxenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric outpatients. J Geriatr Psychiatry Neurol. 1989;52:294-299.
45. DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry. 2003;64(suppl 18):14-19.
46. Kinrys G, Simon NM, Farach FJ, Pollack MH. Management of antidepressant-induced side effects. In: Alpert JE, Fava M, eds. Handbook of Chronic Depression. New York, NY: Marcel Dekker, Inc; 2004:411-446.
47. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry. 1992;53(suppl):61-66.
48. Fava MF. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(suppl 11):37-41.
49. Fava M, Roxenbaum JF, Judge RA, et al. Fluoxetine vs. sertraine and parosetine in major depression: long-term changes in weight. In: New Research Program and abstracts of the 152nd Annual Meeting of the American Psychiatric Association. May 19, 1999; Washington, DC. Abstract NR430:186.
50. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychopharmacol. 2000;20:645-652.
51. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170-1176.
52. Mackle M, Kocsis J. Effects on body weight of the SSRI citalopram. Paper presented at; the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14-18, 1998; Las Croabas, Puerto Rico.
53. Sussman N, Ginsberg DL, Bikoff J, et al. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor-and imipramine-controlled trials. J Clin Psychiatry. 2001;62:256-260.
54. Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk of relapse for depression. Biol Psychiatry. 2002;51:753-761.
55. Thase M, Bartlett C. Reboxetine does not cause weight gain during long-term therapy [abstract]. Eur Neuropsychopharmacol. 2001;11(suppl 3):S215.
56. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(suppl 6):26-31.
57. Hoehn-Saric, Lipey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol. 1990;10:343-345.
58. Rosenbaum JF, Fava M, Hoog SL et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77-87.
59. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: Life-Steps and medication monitoring. Behav Res Ther. 2001;39:1151-1162.
60. Safren SA, Otto MW, Worth JL. Applying cognitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999;6:332-341.